Donate For Public and Patients Store Search

S058 - Pearls: Diagnostic and Therapeutic

Monday, March 4; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Use innovative therapies for patients with complicated conditions, or common maladies unresponsive to commonly effective approaches.
  • Safely and effectively utilize established medications for off label uses
  • Diagnose with dermoscopy and appropriate communication with the pathologist


Faculty will present innovative approaches to dermatologic problems, some treatment resistant, some diagnostically difficult, some using newer drugs and treatments, others reaching back to therapies that worked in the past but may have been forgotten. Off-label and ABM (anecdote-based management) will predominate, with a few evidence based pearls as well. Target audience is the office based dermatologist. Participant are urged to e-mail challenging cases to in advance of the meeting for discussion by the faculty. The more audience participation the merrier!


  • Brodell, Robert T., MD: Bracco – A(H); Corrona, Inc. – I(Grants/Research Funding); IntraDerm Pharmaceuticals – A(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Practical Dermatology – O(H); Regeneron – A(H);
  • Goldenberg, Gary, MD: AbbVie – SP(H); Allergan, Inc – C(H); Anacor Pharmaceuticals, Inc. – C(H); Bayer – SP(H); Bayer Pharmaceuticals – C(H); Castle Biosciences – SP(H); Celgene Corporation – C(H), SP(H); Dermira – A(H); Eclipse Medical – C(H); Eli Lilly and Company – C(Fees), SP(H); Galderma USA – SP(H); Genentech, Inc. – C(H); Janssen Pharmaceuticals, Inc – C(H); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – C(H), SP(H); MelaSciences – C(H); Novartis Pharmaceuticals Corp. – C(H), SP(H); Pfizer Inc. – C(H); Pharmaderm – A(H), I(Grants/Research Funding), SP(H); Ranbaxy Laboratories Limited – C(H); Stiefel a GSK company – C(H), I(Grants/Research Funding); Taro Pharm – C(Fees); Teva Pharmaceuticals USA – C(Fees); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding), SP(H); Xoft – C(H);
  • Lallas, Aimilios, MD, MSc, PhD: 3Gen, LLC – A(EQ); Amgen – I(Fees); Avène – Speaker/Faculty Education(H); Bioderma – SP(H); Elsevier Inc. – O(Fees); Fotofinder – A(EQ); Galderma Laboratories, L.P. – SP(H); La Roche-Posay Laboratorie Pharmaceutique – I(Residency/Fellowship Program Funding), Speaker/Faculty Education(H); LEO Laboratories Ltd (LEO Pharma) – A(H), I(Grants/Research Funding); Novartis – A(H);
  • Lebwohl, Mark, MD: AbbVie – I(Grants/Research Funding); Allergan, Inc. – C(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Arcutis, Inc. – C(H); AstraZeneca – I(Grants/Research Funding); Avotres, Inc. – C(H); BirchBioMed – C(H); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Bristol-Myers Squibb – C(H); Cara Therapeutics – C(H); Castle Biosciences, Inc – C(H); Celgene Corporation – I(Grants/Research Funding); Clinuvel – I(Grants/Research Funding); Corrona, Inc. – O(H); Dermavant Sciences – C(H); Dr. Reddy – C(H); Eli Lilly and Company – I(Grants/Research Funding); Foundation for Research & Education of Dermatology – O(H); Incyte Corporation – I(Grants/Research Funding); Inozyme Pharma – C(H); Janssen Research & Development, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); Leo Pharma Inc – C(H); LEO Pharma, US – I(Grants/Research Funding); Medimmune – I(Grants/Research Funding); Meiji Seika Pharma Co., Ltd – C(H); Menlo Therapeutics – C(H); Mitsibushi Pharma – C(H); Neuroderm LTD – C(H); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Ortho Dermatologics – I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); SCIderm – I(Grants/Research Funding); Theravance Biopharma – C(H); UCB – I(Grants/Research Funding); Verrica Pharmaceuticals Inc – C(H); Vidac Pharma – I(Grants/Research Funding);
  • Stone, Stephen P., MD: Abbott Laboratories – SH(OB); Acuderm, Inc. – B(NC), SH(NC); Centocor Ortho Biotech Inc. – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – SH(OB); OPKO Health, Inc – SH(OB); Pfizer Inc. – I(Grants/Research Funding), SH(OB); Teva – SH(OB); XOMA Corporation – I(NC);
Monday, March 4
1:00 PM
Dr. Stone / Introduction
1:05 PM
Dr. Brodell / Pearls From A Rural Nigerian Mission
1:35 PM
Dr. Lallas / Dermoscopy Pearls
2:15 PM
Dr. Lebwohl / Office Tips
2:50 PM
Dr. Goldenberg / Derm Path Pearls: what's the Pathologist Really Saying
3:20 PM
Dr. Stone / Off Label Tricks and Techniques
3:50 PM
All faculty / Q & A
Event Details
  • Date
    Monday, March 4
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 145B
  • CME Credits
  • Type
  • Aimilios Lallas, MD, MSc, PhD
  • Gary Goldenberg, MD, FAAD
  • Mark Lebwohl, MD, FAAD - Handout
  • Robert T. Brodell, MD, FAAD - Handout